Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma
Year: 2025
Type: article
Study design: Observational Study
Abstract: Objectives To establish a novel Inflammation Prognostic Score Index (IPSI) and evaluate its prognostic value and complementary role to the International Staging System (ISS) in newly diagnosed multiple myeloma (MM).Methods This retrospective study analyzed 98 newly diagnosed MM patients. ROC-derived cutoffs stratified patients by RDW, PLT, NMLR, SII, and SIRI. The IPSI was constructed by assigning 1 point each to elevated RDW, low PLT, and high NMLR, defining three risk groups: 0–1, 2, and 3 risk factor groups. Survival and ISS correlations were evaluated using Kaplan-Meier, Cox, and Spearman’s tests.Results Multivariate analysis confirmed RDW, PLT, and NMLR as independent predictors of overall survival (OS) (all P < 0.05). Based on these, IPSI stratified patients into three risk groups: 0–1, 2, and 3 risk factor groups, with median OS of 24, 21.5, and 14 months, respectively (log-rank P < 0.001). IPSI was an independent prognostic factor (2-risk-factors group: HR = 8.74; 3-risk-factors group: HR = 18.98 vs 0–1-risk-factors group; both P < 0.001) and correlated with ISS stage (rs = 0.35, P < 0.001). Critically, IPSI refined risk stratification within all ISS subgroups (P < 0.001). SII and SIRI correlated with ISS but were not independent prognostic factors.Conclusions As an independent prognostic index that integrates RDW, PLT, and NMLR, IPSI optimizes ISS staging and provides a cost-effective risk stratification tool. It may be a good measure indice of identifying high-risk MM patients in resource constraint setting where access to molecular testing is not available.
Source: Hematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,557
OpenAlex ID: W4413872536